Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral
azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has
come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy
drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.